Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel

Author(s):
Ortmann, O.; Pagani, O.; Jones, A.; Maass, N.; Noss, D.; Rugo, H.; Velde, C. van de; Aapro, M.; Coleman, R.
Published
2011
Publication type
Article / Letter to editor
Adjuvant therapyAromatase inhibitorsBreast cancerMenopausePerimenopauseTamoxifen
Date issued
2011-04-30
Language
English
Is part of
Cancer Treatment Reviews (2011), Vol. 37, no. 2, p. 97-104
hdl
1887/106194
doi
10.1016/j.ctrv.2010.05.005